FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits – Guidance

Clinical trial sponsors should make greater use of off-site centralized monitoring, in place of frequent on-site visits, to ensure the quality of their trials, FDA emphasizes in new draft guidance.